Alembic Pharmaceuticals Ltd Share Price
(APLLTD)
₹883.8▲3.27%
as on 04:01PM, 23 Apr 2025
Alembic Pharmaceuticals Ltd Performance
Day's Low
Day's High
₹852.65Day's Price Range₹908.252 Week's Low
52 Week's High
₹725.252-Week Price Range₹1,303.9
| Returns % | |
| 1 Month Return | -10.78 % |
| 3 Month Return | -12.5 % |
| 1 Year Return | -8.98 % |
| Market Stats | |
| Previous Close | ₹855.80 |
| Open | ₹859.80 |
| Volume | 5.15L |
| Upper Circuit | ₹1,026.95 |
| Lower Circuit | ₹684.65 |
| Market Cap | ₹16,821.87Cr |
Alembic Pharmaceuticals Ltd Fundamentals
P/E Ratio
28.41
PEG Ratio
710.33
Market Cap
₹16,821.87 Cr
P/B Ratio
3.93
EPS
31.33
Dividend Yield
1.12
Sector
Pharmaceuticals
ROE
14.3
Mutual Fund Holdings of Alembic Pharmaceuticals Ltd
| Funds | Holdings | Prev. 5M |
|---|---|---|
 Kotak Small Cap Direct Growth | 2.03% | |
 DSP Midcap Fund Direct Plan Growth | 1.6% | |
 Axis Small Cap Fund Direct Growth | 0.59% | |
| DSP Healthcare Fund Direct Growth | 4.38% | |
| DSP ELSS Tax Saver Fund Direct Plan Growth | 0.81% |
Alembic Pharmaceuticals Ltd Analyst Rating
based on 11 analysts
45.45%
Buy
45.45%
Hold
9.09%
Sell
Based on 11 analysts offering long term price targets for Alembic Pharmaceuticals Ltd. An average target of ₹1054.64
Source: S&P Global Market Intelligence
Alembic Pharmaceuticals Ltd Share analysis
Alembic Pharmaceuticals Ltd price forecast by 11 analysts
Upside of23.23%
High
₹1411
Target
₹1054.64
Low
₹909
Alembic Pharmaceuticals Ltd target price ₹1054.64, a slight upside of 23.23% compared to current price of ₹883.8. According to 11 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Alembic Pharmaceuticals Ltd revenue growth forecast
Expected growth rate Q1, FY2027:31.01%
Forecast
Actual
Including amortisation and stock based compensations
Alembic Pharmaceuticals Ltd EPS growth forecast
EPS estimate Q1, FY2027:59.14%
Forecast
Actual
Source: S&P Global Market Intelligence
Key events for Alembic Pharmaceuticals Ltd
Alembic Pharma Secures USFDA Approval for Carbamazepine - 17 Apr, 2025
Alembic Pharmaceuticals has received final USFDA approval for Carbamazepine Tablets USP, 200 mg, which are therapeutically equivalent to Novartis' Tegretol. The estimated market size is $32 million for the next year.Alembic Pharma Secures USFDA Approval for Injection - 01 Apr, 2025
Alembic Pharmaceuticals has received USFDA approval for Pantoprazole Sodium for Injection, a significant addition to its portfolio, bringing total ANDA approvals to 221. The estimated market size for this product is $48 million for the year ending December 2024.Alembic Partners with Amlan for Poultry Solutions - 25 Mar, 2025
Alembic Pharmaceuticals has entered a strategic agreement with Amlan International to introduce advanced poultry health solutions in India, enhancing productivity and sustainability in the sector.Alembic Pharma's API Facility Passes USFDA Inspection - 22 Mar, 2025
Alembic Pharmaceuticals announced the successful completion of a USFDA inspection at its API-III facility in Karakhadi, Gujarat, with zero observations. This achievement reinforces the company's commitment to quality and regulatory compliance, enhancing its reputation in the global market.
Insights on Alembic Pharmaceuticals Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTFII Holding Up
Foreign Institutions have increased holdings from 3.94% to 4.17% in Dec 2024 quarter
- POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 8.90% to 8.96% in Dec 2024 quarter
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 4 quarters, 1.52K Cr → 1.70K Cr (in ₹), with an average increase of 3.7% per quarter
NO EFFECTAgainst Peers
In the last 1 year, Divis Laboratories Ltd has given 56.9% return, outperforming this stock by 65.8%
- NO EFFECT
Against Peers
In the last 3 years, Torrent Pharmaceuticals Ltd has given 137.6% return, outperforming this stock by 125.8%
- NO EFFECT
Promoter Holding Unchanged
Promoters holdings remained unchanged at 69.61% of holdings in Dec 2024 quarter
NEGATIVE IMPACTRetail Holding Down
Retail Investor have decreased holdings from 10.39% to 10.16% in Dec 2024 quarter
- NEGATIVE IMPACT
Price Dip
In the last 1 month, APLLTD stock has moved down by -10.8%
- NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 2 quarters, 153.41 Cr → 138.42 Cr (in ₹), with an average decrease of 9.8% per quarter
Alembic Pharmaceuticals Ltd Financials
Alembic Pharmaceuticals Ltd Index Inclusions
Alembic Pharmaceuticals Ltd Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 69.61% | 0.00 | |
| Foreign Institutions | 4.17% | 5.77 | |
| Mutual Funds | 8.96% | 0.73 | |
| Retail Investors | 10.16% | ||
| Others | 7.09% |
Alembic Pharmaceuticals Ltd Key Indicators
Alembic Pharmaceuticals Ltd Valuation
Alembic Pharmaceuticals Ltd in the last 5 years
Lowest (11.53x)
March 23, 2020
Today (28.41x)
April 22, 2025
Industry (53.69x)
April 22, 2025
Highest (53.41x)
January 3, 2023
Alembic Pharmaceuticals Ltd Earnings and Dividends
Alembic Pharmaceuticals Ltd Earnings Results
Alembic Pharmaceuticals Ltd’s net profit fell -23.29% since last year same period to ₹138.42Cr in the Q3 2024-2025. On a quarterly growth basis, Alembic Pharmaceuticals Ltd has generated -9.77% fall in its net profits since last 3-months.
Read More about Earnings ResultsAlembic Pharmaceuticals Ltd Dividends May,2024
In the quarter ending March 2024, Alembic Pharmaceuticals Ltd has declared dividend of ₹11 - translating a dividend yield of 1.24%.
Read More about Dividends
Alembic Pharmaceuticals Ltd Technicals Summary
Bearish
Neutral
Bullish
Alembic Pharmaceuticals Ltd is currently in a Bullish trading position according to technical analysis indicators.
Alembic Pharmaceuticals Ltd Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| BUY | ₹16,821.87 Cr | 4.5% | 0.55 | ₹615 Cr | ₹6,228 Cr | |
| BUY | ₹14,662.05 Cr | -2.98% | 0.52 | ₹602 Cr | ₹2,851 Cr | |
| BUY | ₹69,591.93 Cr | 17.76% | 0.56 | ₹3,168 Cr | ₹29,001 Cr | |
| HOLD | ₹85,801.57 Cr | 31.45% | 0.64 | ₹3,854 Cr | ₹19,547 Cr | |
| BUY | ₹65,906.88 Cr | 17.84% | 0.53 | NA | NA |
About Alembic Pharmaceuticals Ltd
Revenue: ₹1,692.74Cr as on December 2024 (Q4 24)
Net Profit: ₹137.70Cr as on December 2024 (Q4 24)
Listing date: 20 Sep, 2011
Chairperson Name: Chirayu R Amin
| Organisation | Alembic Pharmaceuticals Ltd |
| Headquarters | Vadodara |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
FAQs on Alembic Pharmaceuticals Ltd
What is Alembic Pharmaceuticals Ltd price today?
Alembic Pharmaceuticals Ltd share price today stands at ₹883.8, Open: ₹859.8, Previous Close: ₹855.8, High: ₹908.2, Low: ₹852.65, 52 Week High: ₹1303.9, 52 Week Low: ₹725.2.
How to Buy Alembic Pharmaceuticals Ltd Share in India?
- Get a PAN card
- Open a Demat account
- Open a Trading account
- Link your Demat account to your Trading account
- Fund your Trading account
- Place an order to buy Alembic Pharmaceuticals Ltd shares
What are today's traded volumes of Alembic Pharmaceuticals Ltd?
Today's traded volume of Alembic Pharmaceuticals Ltd(APLLTD) is 5.15L.
What is today's market capitalisation of Alembic Pharmaceuticals Ltd?
Today's market capitalisation of Alembic Pharmaceuticals Ltd(APLLTD) is ₹16821.87Cr.
What is the 52 Week High and Low Range of Alembic Pharmaceuticals Ltd?
How much percentage Alembic Pharmaceuticals Ltd is down from its 52 Week High?
Alembic Pharmaceuticals Ltd (APLLTD) share price is ₹883.8. It is down -32.22% from its 52 Week High price of ₹1303.9
How much percentage Alembic Pharmaceuticals Ltd is up from its 52 Week low?
Alembic Pharmaceuticals Ltd (APLLTD) share price is ₹883.8. It is up 21.87% from its 52 Week Low price of ₹725.2